NCT01687101 is a NA clinical trial of STOPAIN topical gel in Migraine, sponsored by Thomas Jefferson University.

Who is sponsoring NCT01687101?

NCT01687101 is sponsored by Thomas Jefferson University.

What drugs are being tested in NCT01687101?

Interventions in NCT01687101: STOPAIN topical gel.

What condition does NCT01687101 study?

NCT01687101 studies Migraine, Headache.

Is NCT01687101 still recruiting?

NCT01687101 is currently completed. Last updated 5 May 2017.

Are results published for NCT01687101?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2017-05-05 · How we verify

NCT01687101

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Efficacy and Tolerability of STOPAIN in the Treatment of a Single Migraine Attack

Completed NA Results posted Last updated 5 May 2017

What this trial tests

NA trial testing STOPAIN topical gel in Migraine in 32 participants. Completed in 1 May 2013.

Timeline

1 May 2012

Primary endpoint
1 May 2013

1 May 2013

Quick facts

Lead sponsor	Thomas Jefferson University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	32
Start date	1 May 2012
Primary completion	1 May 2013
Estimated completion	1 May 2013
Sites	1 location across United States

Drugs / interventions tested

STOPAIN topical gel — full drug profile →

Conditions studied

Migraine — all drugs for Migraine →
Headache — all drugs for Headache →

Sponsor

Thomas Jefferson University

Who can join

Adults 18 to 65, any sex, with Migraine or Headache. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Efficacy of STOPAIN in the Acute Treatment of Migraine
Time frame: 2 hours after the time of gel application
To evaluate the efficacy of STOPAIN in the acute treatment of migraine as measured by Pain Freedom (headache pain intensity level equal to "no pain") at 2 hours post dose using a four point numeric rating scale (0=no pain, 1= mild pain, 2=moderate pain, 3=severe pain).

Sponsor's own description

This is an open label pilot study of 25 subjects with a diagnosis of episodic migraine with or without aura. STOPAIN is an over-the-counter product that is used for the temporary relief of minor aches and pains of muscles and joints associated with simple backache, arthritis, strains, bruises and sprains. We plan to have subjects apply the product during a single migraine attack to see if it will alleviate the headache pain and associated symptoms.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

TRPM8 Channels: Advances in Structural Studies and Pharmacological Modulation.
Izquierdo C, Martín-Martínez M, Gómez-Monterrey I, González-Muñiz R. · · 2021 · cited 54× · PMID 34445208 · DOI 10.3390/ijms22168502
Exploring Novel Therapeutic Targets in the Common Pathogenic Factors in Migraine and Neuropathic Pain.
Tajti J, Szok D, Csáti A, Szabó Á, et al · · 2023 · cited 47× · PMID 36835524 · DOI 10.3390/ijms24044114
The distinctive role of menthol in pain and analgesia: Mechanisms, practices, and advances.
Li Z, Zhang H, Wang Y, Li Y, et al · · 2022 · cited 29× · PMID 36277488 · DOI 10.3389/fnmol.2022.1006908

Verify or expand the search:

Other recruiting trials for Migraine

Currently open trials in the same condition.

NCT07419607 — MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducat · NA · recruiting
NCT07487701 — Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study · NA · active not recruiting
NCT07343427 — Impact of GON PRF on Central Sensitization in Migraine Patients · NA · active not recruiting
NCT07336056 — Nerivio Efficacy Under High-Frequency Use · Phase 4 · active not recruiting
NCT07385755 — Desvenlafaxine for Preventive Treatment of Frequent Migraines · NA · active not recruiting

Other Thomas Jefferson University trials

Trials by the same sponsor.

NCT07526480 — Improving Dementia Care in Primary Practice · NA · not yet recruiting
NCT07414550 — Radiotherapy for Refractory Hidradenitis Suppurativa · NA · not yet recruiting
NCT07402018 — Intra-aortic Balloon Counterpulsation (IABC) Compliance · recruiting
NCT07217197 — Respiratory Monitoring System That Detects & Predicts OIRD · NA · enrolling by invitation
NCT07145099 — The IMPACT Study: Personalized Physical Therapy for Better Recovery and a Stronger Core After Hernia Surgery · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01687101 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Thomas Jefferson University
Last refreshed: 5 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01687101.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing